Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 95,412 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 95,412 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76. Following the transaction, the director directly owned 2,010,508 shares of the company’s stock, valued at approximately $1,467,670.84. This represents a 4.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total transaction of $45,849.00.

Werewolf Therapeutics Trading Down 8.1%

Shares of HOWL traded down $0.06 during mid-day trading on Wednesday, reaching $0.68. 444,465 shares of the stock traded hands, compared to its average volume of 413,866. The firm has a fifty day moving average price of $0.81 and a 200 day moving average price of $0.89. The company has a market cap of $33.05 million, a price-to-earnings ratio of -0.50 and a beta of 0.54. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.14. On average, sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Analyst Upgrades and Downgrades

HOWL has been the subject of several research reports. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.75.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the period. Vanguard Group Inc. grew its holdings in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the 2nd quarter worth $409,000. Finally, Citadel Advisors LLC bought a new stake in Werewolf Therapeutics in the 3rd quarter worth $304,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.